Bisphosphonate Use Linked to Reduced Colorectal Cancer Risk

This article originally appeared here.
Share this content:
Bisphosphonate Use Linked to Reduced Colorectal Cancer Risk
Bisphosphonate Use Linked to Reduced Colorectal Cancer Risk

(HealthDay News) – Exposure to bisphosphonates (BPs) is associated with a reduction in the risk of colorectal cancer (CRC), a reduction that is significant only for risedronic acid, according to a study published in the March 1 issue of Cancer.

Harminder Singh, MD, MPH, from the University of Manitoba in Winnipeg, Canada, and colleagues identified 5,425 patients diagnosed with CRC from 2000 to 2009 who had been living in Manitoba for at least five years prior to diagnosis. Using incidence-density sampling, each case was matched for age, sex, and duration of residence in Manitoba with ten controls (54,242 controls). Exposure to BPs was determined, and its effect on CRC incidence was assessed, after adjusting for healthcare use, medical procedures, socioeconomic status, and pre-existing health conditions.

The researchers found that, on multivariate analysis, BP exposure correlated with a reduced risk of CRC (two to thirteen prescriptions over at least five years: odds ratio [OR], 0.84; 95% confidence interval [CI], 0.71 to 1.00; ≥14 prescriptions over at least five years: OR, 0.78; 95% CI, 0.65 to 0.94). The effect was significant only for risedronic acid (OR, 0.50) when the effect of specific BP agents was assessed. Increasing duration or cumulative dose of alendronic acid had no significant effect.

"Additional studies are needed to confirm these findings and to determine the cost-benefit ratio for the use of BPs, a class of agents commonly used in the elderly, which comprise a population at risk for both osteoporosis and CRC," the authors write.

One of the authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs